Yair Lotan, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Synergo
    Date added:
    Date updated:
    07/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Engene
    Date added:
    Date updated:
    07/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    nucleix
    Date added:
    Date updated:
    07/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    nucleix
    Date added:
    Date updated:
    07/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Merck Inc
    Date added:
    Date updated:
    07/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    astra zeneca
    Date added:
    Date updated:
    07/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    vessi Medical
    Date added:
    Date updated:
    07/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    Urogen
    Date added:
    Date updated:
    07/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    MDxHealth
    Date added:
    Date updated:
    07/15/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other
    Ineligible company:
    MDxHealth
    Date added:
    Date updated:
    07/15/2024

Pages

Return to Sequencing of Agents and Combination of Treatment Options for Bladder Cancer Podcast (2019)